Oncogenes in human testicular cancer: DNA and RNA studies. by Peltomäki, P. et al.
Br. J. Cancer (1991), 63, 851-858
1991
Oncogenes in human testicular cancer: DNA and RNA studies
P. Peltomiikil, 0. Alfthan2 & A. de la Chapelle'
'Department ofMedical Genetics, University ofHelsinki, Haartmaninkatu 3, 00290 Helsinki; 2The Second Department ofSurgery,
Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.
Summary Oncogene dosage and expression were studied in 16 testicular neoplasms, 14 of germ cell and two
of non-germ cell origin. In comparison with normal DNA, tumour DNA of a total of eight patients (seven
with germ cell neoplasm and one with testicular lymphoma) showed increased dosages of KRAS2, PDGFA,
EGFR, MET and PDGFB. The most frequent (occurring in six tumours) and prominent (up to 3-4-fold)
increases were detected in the dosages of KRAS2 (on chromosome 12p) and PDGFA (chromosome 7p),
relative to a reference locus from chromosome 2. Importantly, there was a similar increase in 12p dosage in
general in these tumours, suggesting the presence of the characteristic isochromosome 12p marker. On the
contrary, possible 7p polysomy (assessed by molecular methods) did not explain the PDGFA (or EGFR)
changes in all cases. NRAS, MYCN, CSFIR, MYB, MYC, ABL, HRASI, TP53, and ERBB2 did not reveal
any consistent alterations in tumour DNA. In RNA dot blot assays the expression of KRAS2, PDGFA,
EGFR, or MYC was generally not increased in the tumour samples when compared to that in normal
testicular tissue of the same patients although there was interindividual variation in mRNA levels. It thus
appears that while oncogene dosage changes occur in a proportion of testis cancers, they are often part of
changes in large chromosomal regions or whole arms and are seldom accompanied by altered expression.
Tumorigenesis is considered to be a multistep process where
accumulation of several defects results in the deregulation of
cell growth. In human testicular cancer these putative pro-
cesses are poorly understood. Involvement of tumour
suppressor genes that act in a recessive manner is suggested
by loss of heterozygosity in some areas of the genome in
tumour DNA (Lothe et al., 1989; Radice et al., 1989; Ruk-
stalis et al., 1989; Peltomaki et al., 1990). As cellular
oncogenes are thought to participate in the regulation of cell
differentiation - which is a prominent feature of testes -
alterations of oncogenes are of obvious interest in testicular
tumours of germ cell origin. Mutation, rearrangement, and
amplification are examples of molecular mechanisms that
may lead to altered function through increased production of
normal oncogene proteins or production of abnormal pro-
teins.
The objective of the present investigation was to explore
the involvement of oncogenes in testicular tumours. More
specifically, we wished to determine (1) whether oncogene
amplification occurs, (2) whether amplification resulted from
polysomy of an entire chromosome arm or represented gene-
specific amplification, and (3) whether changes in DNA
dosage were accompanied by altered gene expression. Results
obtained in a series of 16 patients with testicular neoplasm
are presented.
Materials and methods
Patients andsamples
The material was derived from 16 patients with sporadic
testicular tumours. Histological diagnoses, clinical stages, and
scrum levels of tumour markers are shown in Table I. Four-
teen tumours were of germ cell and two of non-germ cell
origin. A case (No. 10) of malacoplakia (a benign condition
of unknown etiology which often results in a tumour-like
formation in the testis) was included for comparison. In
addition, we used the Tera-l cell line (No. HTB105, obtained
at passage 51 from the American Type Culture Collection,
ATCC). The line was established from a metastatic embryo-
nal carcinoma by Fogh (1978).
Samples offresh tumour tissue, epididymis, and apparently
normal testicular tissue as well as heparinised venous blood
were obtained at the time of orchiectomy. The samples and
case histories of patients 1-14 were described in greater
detail previously (Peltomaki et al., 1989 and 1990). Histo-
logically, all the tumour and non-tumour samples could be
considered representative (with the possible exception of the
lymph node samples from patient 3; Peltomaki et al., 1989).
As control samples for expression studies normal testicular
tissue was obtained from six patients (all over 60 years) who
underwent bilateral orchiectomies due to prostatic carcin-
oma.
Southern blot analysis
High-molecular-weight DNA was extracted from blood and
tissue samples by established methods (Kunkel et al., 1977;
Table I Histology, stage, and tumour marker status in the patients
studied
Patient Histological Stage at Serum levels of
No. diagnosisa diagnosis" HCG and AFP
1 Teratocarcinoma (MTI) IIA S-HCG and S-AFP
elevated
2 Seminoma III S-HCG elevated
3 Embryonal carcinoma IIA S-HCG and S-AFP
(MTU)C elevated
4 Seminoma and mature I Not elevated
teratoma (TD)
5 Teratocarcinoma (MTI) I Not elevated
6 Seminoma I Not elevated
7 Seminoma I Not elevated
8 Seminoma I Not elevated
9 Seminoma I Not elevated
13 Seminoma IIB Not elevated
14 Teratocarcinoma (MTI) IIB Not elevated
15 Seminoma I Not elevated
16 Teratoma (TD) I Not elevated
17 Seminoma I S-HCG elevated
11 Malignant lymphoma
12 Malignant lymphoma
10 Malacoplakia
Abbreviations: HCG, human chorionic gonadotropin; AFP, a-
fetoprotein; MTI, malignant teratoma intermediate; MTU, malignant
teratoma undifferentiated; TD, teratomadifferentiated. aThe American
classification (Mostofi & Sobin, 1977). The corresponding British
terminology (Pugh, 1976) is indicated in parentheses; bRoyal Marsden
Hospital staging classification (Peckham, 1988); cOnly lymph node
metastases studied.
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Maniatis et al., 1982). DNA (5-7.5 lAg) was digested with
appropriate restriction endonucleases (from GIBCO-BRL,
Gaithersburg, MD, USA or Promega-Biotec, Madison, WI,
USA). Digested DNA samples were electrophoresed in 0.7%
or 0.8% agarose gels and transferred by the method of
Southern (1975) to nitrocellulose (Schleicher & Schuell,
Dassel, Germany) or nylon (Zeta-Probe, Bio-Rad, Rich-
mond, CA, USA) membranes. DNA probes were labelled
with 32P by nick-translation (Rigby et al., 1977) or random
primer synthesis (Feinberg & Vogelstein, 1984). Prehybridi-
sations and hybridisations were performed overnight in
appropriate mixtures (as described by Bianchi et al., 1988;
Peltomaki et al., 1989). Membranes were washed at appropri-
ate stringencies and the films exposed at -70'C for 1-10
days using intensifying screens.
Assessment ofgene dosage
The amounts of normal and tumour DNA from each patient
were adjusted to be as equal as possible in a given experi-
ment. The membranes were first hybridised with various
oncogene probes and then rehybridised with reference
probes. Two kinds of references were used. First, a probe
from the short arm of chromosome 2 (CK, see below) was
used to detect an altered dosage. This locus has not been
reported to be involved or affected in testicular cancer.
Second, a probe from the same chromosome arm on which
the oncogene is located was used to assess the specificity of
the observed changes.
Intensities of bands were measured using an LKB 2202
Ultro Scan Laser Densitometer. The dosage of a particular
oncogene in tumour DNA relative to normal DNA was
determined from intensity ratios obtained as follows:
Oncogene signal/reference signal in tumour DNA
Oncogene signal/reference signal in normal DNA
RNA dot blot analysis
Total RNA was isolated from tissue samples and the cell line
according to the method of Chomczynski & Sacchi (1987).
RNA samples were analysed in dot blot experiments; North-
ern blots were omitted due to the scarcity of material from
the biopsies. RNA was denatured in formaldehyde and spot-
ted onto nitrocellulose using HYBRI DOT Manifold (from
BRL, Gaithersburg, MA, USA). Serial dilutions (mostly of 6,
3, 1.5 and 0.75fig) were used of each RNA sample. Prehy-
bridisations, hybridisations, filter washes and autoradio-
graphy were performed essentially as with Southern blots.
Membranes were washed at high stringency (with final
washes in a solution containing 0.1 x SSC + 0.1% SDS at
+65C) to reduce nonspecific hybridisation signal. Before
rehybridisation the previous probe was removed with boiling
water and the elimination of the probe was controlled by
exposing the membrane to an X-ray film overnight at - 70°C
with an intensifying screen.
DNA probes
Probes representing 14 oncogenes were utilised (Table II). In
addition, we used genomic probe pH 3-4 (Lalande et al.,
1986) and cDNA probe p2R3.8 (Friend et al., 1986) from the
retinoblastoma gene. Probe pH 3-8 was purchased from
ATCC/S. Latt and p2R3.8 was provided by M. Norden-
skiold. The samples of patients 11 and 12 with malignant
lymphoma were also studied with an immunoglobulin heavy
joining region gene probe (JH; Ravetch et al., 1981) and an
immunoglobulin kappa constant region gene probe (CK;
Hieter et al., 1982) to confirm the histologic diagnosis. Both
immunoglobulin gene probes were provided by P. Leder.
In Southern hybridisations the immunoglobulin kappa
constant region gene probe from the short arm of chromo-
some 2 (see above) was used as a quantitative reference to
detect an altered dosage. Signals obtained with probes
pASpc7 (derived from the argininosuccinate synthetase pseu-
dogene 1, Daiger et al., 1984), pNJ-3/3.5 (derived from the
collagen type I alpha 2 gene locus, Tsipouras et al., 1984),
pPRPl 12.2RP (derived from the proline-rich protein sub-
family 1, Azen et al., 1984), and universal bcr (representing
the breakpoint cluster region, Groffen et al., 1984) were used
to represent 7p, 7q, 12p and 22q dosages, respectively. The
pAScpc7 probe was provided by A. Beaudet and W. O'Brien,
pNJ-3/3.5 by P. Tsipouras, and universal bcr by J. Groffen.
Probe pPRPI 12.2RP was obtained from ATCC/O. Smithies.
In RNA studies cDNA probe pHcGAP (derived from the
glyceraldehyde-3-phosphate dehydrogenase gene, Tso et al.,
1985) was used as a quantitative standard. Expression levels
were also standardised with genomic probe pHRL83-IVS4
(Gunning et al., 1984). That represents the human cardiac
actin gene locus but cross-hybridises with human P-actin
mRNA. Probes pHcGAP and pHRL83-IVS4 were obtained
from ATCC (depositors R. Wu and L. Kedes, respectively).
Results
DNA studies
Using probes listed in Table II no restriction fragments of
unexpected size were observed by Southern hybridisation in
Table II Oncogene probes used
Locus Type of Chromosomal
symbol' Probe insert" location Provided by Reference
NRAS p52c- G lpl3 ATCC/R. Weinberg Murray et al., 1983
MYCN pNB-1 G 2p24 ATCC/J. Bishop Schwab et al., 1983
CSF1R pcfmsl04 c 5q33-q35 ATCC/A. Ullrich Coussens et al., 1986
MYB pHM2.6 G 6q22-q23 ATCC/D. Stehelin Dozier et al., 1986
EGFR pE7 c 7pI3-pI2 ATCC/G. Merlino, Xu et al., 1984
I. Pastan
PDGFA DI c 7p22-p2I or C. Betsholtz Betsholtz et al., 1986
qI 1.2-q21.1
MET MetH G 7q31 G. Vande Woude Zengerling et al., 1987
Park et al., 1988
MYC pHSR-1 G 8q24 ATCC/J. Bishop Alitalo et al., 1983
ABL pablK2 G 9q34 ATCC/R. White Srinivasan et al., 1981
HRAS1 pT24-C3 G lIpl5.5 ATCC/M. Barbacid Santos et al., 1982
KRAS2 p640 G 12pl2.1 R. Weinberg McCoy et at., 1983
pSW 1-1 c ATCC/R. Weinberg McCoy et al., 1984
c-K-ras(Pr-i) c Oncogene Science Shimizu et al., 1983
TP53 pHp53B c l7pl3.1 ATCC/D. Givol Zakut-Houri et al., 1985
ERBB2 pCER204 c 17qll-qI2 ATCC/T. Yamamoto Semba et al., 1985
PDGFB pSM-l c 22ql2.3-ql3.1 ATCC/R. Gallo Clarke et al., 1984
'Human Gene Mapping 10, 1989; bG = genomic, c = cDNA.ONCOGENE DOSAGE AND EXPRESSION IN TESTIS CANCER 853
any tumour sample. However, the lymphoma tumours of
patients 11 and 12 were characterised by clonal rearrange-
ments of the immunoglobulin heavy chain genes (both
patients) and the kappa light chain gene (patient 11) (not
shown). Consistent dosage changes were found neither with
oncogene probes representing the NRAS, MYCN, CSF1R,
MYB, MYC, ABL, HRAS1, TP53, and ERBB2 loci, nor
with probe pH 3-8. On the contrary, probes consisting of
KRAS2, PDGFA, EGFR, MET, and PDGFB sequences
revealed dosage alterations relative to the dosage of 2p (a
reference) in tumour DNA of totally eight patients when
compared to normal DNA of the same patients. In Tera-l
cell line the dosage of different oncogenes was determined
using DNA from normal tissue samples of patient 16 (run in
the same electrophoretic gels) for comparison (as no normal
tissue of the patient from whom the Tera-1 cell line was
derived was available).
KRAS2
In comparison with normal DNA tumour DNA of six
patients with germ cell neoplasm showed an increase (1.6-
3.6-fold) in KRAS2 dosage (from 12p) with respect to the
reference locus CK (from 2p) (Figure 1 and Table III). There
was an essentially parallel increase in the pPRP112.2RP sig-
nal (used to standardise the 12p dosage). In the Tera-l cell
line the dosage of KRAS2 was 5.2 and 1.0 relative to the
immunoglobulin kappa constant region gene locus and the
salivary proline-rich protein gene locus, respectively. The
former ratio is in agreement with that reported previously
relative to MOS (Wang et al., 1987). The latter ratio suggests
that the increase in the KRAS2 dosage most likely resulted
from chromosomal changes involving the short arm of
chromosome 12 as in the fresh tumours described above.
PDGFA and EGFR
Tumour DNA of five patients with germ cell neoplasm (Nos.
2, 5, 7, 13, and 14) revealed a relative increase in PDGFA
dosage (Figure 2 and Table III). The alteration was evident
with both CK (from 2p) and pAScpc7 (from 7p) used as
references. The relative intensity ratios varied between 1.8
and 3.0. The PDGFA change was accompanied by an in-
crease in EGFR dosage in patient 7 and a borderline increase
in patients 13 and 14. On the contrary, no change in EGFR
was observed in patients 2 and 5 (but they showed an
increase in PDGFB dosage in their tumour DNA, see below).
The Tera-1 cell line showed a clearly increased intensity ratio
(2.5) of EGFR relative to the 7p reference signal. Patient 12
with testicular lymphoma revealed increased dosages of
PDGFA and EGFR (Figure 2 and Table III).
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Figure 1 DNA (5f&g) from blood (B), normal testicular tissue (N), epididymis (E), and tumour (T) tissue of seven patients with
germ cell neoplasm and DNA (T*: 2.5iLg, T: 5 sg) from the Tera-l cell line. Tumour DNA of patients 1, 2, 5, 7, 14 and 17 showed
an increase in the relative dosage of KRAS2 while patient 16 exemplifies a tumour without change. TaqI-digested DNA samples of
the patients and the cell line were hybridised with p640 (representing KRAS2) and rehybridised successively with CK (a
non-12p-reference) and pPRPl 12.2RP (a 12p-reference). p640 detects a TaqI RFLP with allelic fragments of 3.3 and 5.7 kb. Probe
CK hybridises to a fragment of approximately 12 kb and pPRPI 12.2RP to fragments between 7 and 1.2 kb. DNA samples from
patients 16, 17 and the Tera-I cell line were electrophoresed separately from those of the others.854 P. PELTOMAKI et al.
Table HI Changes in thedosage ofKRAS2, PDGFA, EGFR, MET, and PDGFB in tumourDNA relative to normalDNA
from eight patients with testicular neoplasm and in the Tera-1 cell line
Patient KRAS2/ KRAS2/ PDGFA/ PDGFA/ EGFRI EGFR/ METI METI PDGFB/ PDGFB/
No. CK pPRP1J2.2RP CK pASpc7 CK pASpc7 CK pNJ-3/3.5 CK Univ. bcr
1 3.6 1.5 N N N N 1.8 1.3 N N
2 1.6 1.0 2.5 3.3 N N 3.3 0.8 2.2 2.3
5 3.5 1.6 3.0 2.8 N N N N 3.0 3.0
7 1.8 1.0 2.9 3.3 2.5 3.3 N N N -
13 N N 2.7 1.9 N (1.4) 1.0 N N N N
14 2.0 1.0 1.8 2.3 N (1.4) 1.6 N N N N
17 1.6 0.8 N N N N N N
12 N - 1.7 1.8 1.7 1.5 - 4.0 2.9
Tera-1 5.2 1.0 1.9 1.1 5.2 2.5 N N
Abbreviations: N, no change, -, Not determined. The dosage changes are expressed as relative intensity ratios that were
determined by densitometric analysis as described in the text (normal ratio = 1.0±0.4). The dosage ofeach oncogene was
calculated relative totheimmunoglobulin kappaconstantregiongenelocus(from2p) andalocusfromthe samechromosome
arm on which the oncogene is located. Densitometry was performed on several autoradiograms per oncogene whenever
possible and the mean of the intensity ratios was calculated.
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Figure 2 DNA (5jig) from blood (B), epididymis (E), and
tumour (T) ofeight patients with testicular malignancy and DNA
(5pg) from the Tera-l cell line. Tumour DNA samples of
patients 2, 5, 7, 12, 13, 14, and Tera-l revealed dosage changes of
PDGFA and/or EGFR whereas patients I and 16 are examples
of cases without changes. The samples were digested with Hind-
III. In a the membrane was hybridised with a probe representing
PDGFA and rehybridised with CK (a reference from 2p). The
PDGFA probe and the CK probe hybridise to fragments of about
18 kb and 11 kb, respectively. In b the membrane was con-
secutively hybridised with probes for PDGFA, EGFR, and probe
pAS(pc7 (a 7p reference). The probes detect fragments of approx-
imately 18 kb, 17 kb and I kb, respectively.
MET
Hybridisation with pmetH probe yielded enhanced signals in
tumour DNA samples of patients 1 and 2. This probably
reflected increased 7q dosages in general and was not indica-
tive of specific amplification (Figure 3 and Table III).
Figure 3 Blood (B) and tumour (T) DNA samples of patients 1
and 2, digested with EcoRI and hybridised and rehybridised with
probes pmetH (representing MET), CK (a non-7q reference), and
pNJ-3/3.5 (a 7q reference). The pmetH probe detects a fragment
of about 2kb and the CK probe a fragment of 2.5 kb. Probe
pNJ-3/3.5 hybridises to allelic fragments of 13 and 3.5 kb.
PDGFB
An increase in the relative dosage of PDGFB (from 22q)
appeared in patients 2 and 5 with germ cell neoplasm (Figure
4 and Table III). Intensities of restriction fragments repre-
senting the universal bcr probe were comparable to those
obtained with the CK probe; thus 22q polysomy was not
obviously an explanation of the observed PDGFB changes.
The increases in PDGFB dosage were of the same magnitude
as the PDGFA changes in those two patients. Patient 12 with
malignant lymphoma also showed an enhancement of PDGFB
signal.
RNA studies
Dot blots containing total RNA from tumour and whenever
possible, normal testicular tissue of the patients were succes-
sively hybridised with probes KRAS2, PDGFA, EGFR and
MYC and thereafter with probes pHcGAP and pHRL83-
IVS4 (see Materials and. methods) to standardise expression
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Figure 4 Normal (B, blood, E, epididymis) and tumour (T)
DNA samples of patients 2, 5, and 12 showing increases in
PDGFB dosage as well as the Tera-1I cell line and patient 16
representing negative findings. The samples were digested with
Hindlll. Hybridisation was with a probe derived from the
PDGFB locus and rehybridisations were with CK (a non-22q
reference) and a universal bcr probe (a 22q reference). The
PDGFB probe detects a restriction fragment length polymor-
phism with allelic fragments of 22.6 and 19.4 kb. CK hybridises to
an 11I kb fragment and the universal bcr probe to fragments of
11I kb and 4.5 kb. The samples of patients 2 and 5 were electro-
phoresed separately from those of the others.
levels. KRAS2, PDGFA and MYC showed detectable
expression in tumour and normal testicular tissues under
stringent filter washing conditions. Under similar conditions
no specific signal was obtained in hybridisation of the dot
blot with a probe derived from the EGFR gene (not shown).
As a common observation the mRNA level of a particular
oncogene varied between tumour samples as well as normal
tissue samples of different individuals relative to the stan-
dards used. Of note, when the tumour of each patient was
compared to normal testis from the same individual roughly
equal expression levels were found. Representative examples
are given in Figures 5 and 6.
Figure 5 shows serial dilutions of total RNA from 10
tumours representing different histologies as well as three
normal testes from control males (see Materials and
methods). The membrane was hybridised successively with
probes representing the KRAS2 locus and the PDGFA locus
and the hybridisation signals were compared to the V-actin
mRNA levels. The relative expression of KRAS2 was clearly
higher in tumours of patients 1, 5, 7, 9, 13, 14 and 15 than in
tumours of patients 2, 6, and 8. On the contrary, PDGFA
revealed only minor variation in expression between different
samples. At rehybridisation of the blot with probe pHcGAP
from the glyceraldehyde-3-phosphate dehydrogenase gene sig-
nal intensities directly proportional to those of the actin
probe were obtained except in patients and 5 whose
tumours showed clearly elevated mRNA levels (see below).
The essential similarity of expression levels in normal and
tumour tissue of the same patient is exemplified by KRAS2
in Figure 6. The tumour RNA samples (from three semin-
omas and three nonseminomas) shown in Figure 6 represent
a part of a duplicate series of that presented in Figure 5. The
dot blot was hybridised with a KRAS2 probe (a) and re-
hybridised with probe pHcGAP from the glyceraldehyde-3-
phosphate dehydrogenase gene (b) - both probes map to the
short arm of chromosome 12. In the tumours of patients 1
and 5 there was an elevation in the expression of the glyce-
raldehyde-3-phosphate dehydrogenase gene accompanied by
a smaller increase in KRAS2 expression in patient 1 and no
increase in KRAS2 expression in patient 5. This obviously
reflected the presence of one or several isochromosome 12p
markers and correlated well with the Southern hybridisation
results that showed the highest dosages of 12p in precisely
these two tumours (see above). The membrane in Figures 6a
and b was further hybridised with a probe derived from the
retinoblastoma gene (c). It showed similar expression levels in
normal and tumour samples of the patients except in patient
5 who revealed a higher retinoblastoma gene mRNA level in
normal testis relative to his tumour. Figure 6d (hybridisation
result obtained with the actin probe) shows that the lanes
representing tumour and normal testicular tissue samples
from patient 5 with expression changes of two different kinds
contained roughly equal amounts of hybridisable RNA.
Discussion
At present only a few reports of oncogene alterations in
human testis cancer exist. Cytogenetically a specific chromo-
some marker has been found in more than 80% of testicular
germ cell tumours: an isochromosome for the short arm of
chromosome 12 [i(12p)] (Castedo et al., 1988; Samaniego et
al., 1990). The i(12p) copy number has been reportd to have
prognostic significance (Bosl et al., 1989). It is not known,
however, which of the genes carried by 12p are associated
with the pathogenetic events in testicular cancer.
The KRAS2 oncogene is one obvious candidate. The gene
has been shown to be affected by point mutations or ampli-
fication in a wide variety of human tumours or tumour cell
lines, including pancreas (Almoguera et al., 1988), colon
(Vogelstein et al., 1988), and lung (Taya et al., 1984). In
seminoma tumours Mulder et al. (1989) found mutations at
codons 12 or 61 of the KRAS2 gene (and the NRAS gene)
with a frequency of 40%. These mutations were not, how-
ever, detected in human non-seminoma cell lines with in-
creased copy numbers of 12p (Dmitrovsky et al., 1990).
Published reports of KRAS2 dosage and expression in testis
cancer are mainly based on cell lines. Wang et al. (1987) and
Dmitrovsky et al. (1990) observed 4-6-fold increases in
KRAS2 dosage in non-seminoma cell lines relative to a
non-12p reference locus. However, with a reference from 12p
specific amplification of KRAS2 could not be demonstrated
(Dmitrovsky et al., 1990). Analogous findings were reported
by Mulder et al. (1989) in primary seminomas. On the other
hand, an increased gene dosage does not necessarily result in
overexpression (Wang et al., 1987) and conversely, enhanced
expression may occur without any evidence of amplification
at the DNA level (Monnat et al., 1987). Our present findings
are generally consistent with the above observations and
emphasise that control probes from the same chromosome
should always be used.
The PDGFA and PDGFB genes encode A- and B-chains
of the platelet-derived growth factor and are located on
chromosome 7p and 22q, respectively. They are expressed
independently of each other in human leukaemia and solid
tumour cell lines as well as in certain normal cells (Betsholtz
et al., 1986; Alitalo et al., 1987). In a study of Slamon et al.
(1984) PDGFB transcripts were not found in any of 54 fresh
human tumours, including one germ-cell tumour. EGFR in
turn is shown to be amplified in human epidermoid car-
cinoma (Merlino et al., 1984; Hollstein et al., 1988). Expres-
sion of EGFR is carefully regulated in normal cells, but its
expression has been detected, apart from epidermoid car-
cinoma cells, in cell lines derived from the female urogenital
system (Xu et al., 1984). In the present study detectable (up
to 3-fold) increases in DNA dosage of PDGFA, PDGFB, or856 P. PELTOMAKI et al.
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Figure 5 Dot blot containing total RNA from testicular tumours of 10 patients (Nos. between 1 and 15) and
testicular tissue of three of control males without any testicular malignancy (I-111). The blot was hybridised with
probe c-K-ras (Pr-1) representing KRAS2 a, a PDGFA probe b and the actin probe pHRL83-IVS4 c. After
hybridisations the membrane was washed at high stringency and exposed for 3 a, 4 b, or 6 days c.
a
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Figure 6 Dot blot containing total RNA from tumour (T) and normal testicular (N) (or epididymal, E) tissue of
six patients with testicular germ cell malignancy (Nos. between I and 17). Hybridisations were with probes
pSWII-I representing KRAS2 a, pHcGAP derived from the glyceraldehyde-3-phosphate dehydrogenase gene b,
p2R3.8 derived from the retinoblastoma gene c, and the actin probe pHRL83-IVS4 d. Exposure times of the
autoradiograms were 2 a, 3 b, or 6 days c,d.
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EGFR were observed in neoplastic tissue from a total of six
patients out of 16. The signal enhancement in these cases
exceeded that resulting from apparent aneuploidies of the
respective chromosome arms (7p and 22q). As the tumours
of the present series did not, however, reveal enhanced
expression of PDGFA or EGFR in RNA dot blot assays the
significance of the above amplifications remains unknown so
far.
Other oncogenes reported to have been involved in testi-
cular neoplasia include members of the myc family. Sikora et
al. (1985) observed increased expression of MYC in semino-
mas. These authors also reported correlation between MYC
expression and the grade of differentiation of a teratoma
tumour: the more undifferentiated a teratoma the lower level
of detectable c-myc protein. An elevated expression of
MYCN (in the absence ofgene amplification) was detected in
one seminoma tumour by Saksela et al. (1989). Definite
alterations in the myc genes were not observed in the present
study.
In addition to oncogenes, we studied the dosage and ex-
pression of the retinoblastoma susceptibility gene that
represents tumour suppressor genes. Structural alterations
and/or reduced expression of this gene have been observed,
apart from retinoblastoma and osteosarcoma, in breast
cancer (Lee et al., 1988), small cell lung cancer (Harbour et
al., 1988), and also in a germ cell tumour of the testis
(Saksela et al., 1989). Two-fold or greater increases in dosage
and expression of the retinoblastoma gene were in turn
reported by Gope et al. (1990) in human colorectal car-
cinomas. Except for the finding of a lower level ofexpression
in tumour vs normal tissue in a single case further evidence
of the retinoblastoma gene playing a role in testis tumours
did not come out in the present investigation.
There was a slight over-representation of nonseminoma
and clinical stage greater than I, but no straightforward
association of oncogene changes with the clinical stage or the
histologic subtype was found in this tumour series. It is
noteworthy that all primary tumours that produced elevated
serum levels of tumour markers were also characterised by
changes in oncogene dosage. Oncogene changes in the pre-
sent study and allelic dosage changes reported previously
(Peltomiiki et al., 1990), though causally related in some
cases, coexisted in several tumours. The situation is ana-
logous to colon carcinoma where multiple steps - DNA
hypomethylation, loss of alleles on chromosomes 5, 7 and 18,
and activation of ras oncogenes - ultimately lead to a malig-
nant phenotype (Vogelstein et al., 1988).
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